Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
|Videos|March 24, 2021
Dr. Klein discusses 20-year data on Oncotype DX Genomic Prostate Score
Author(s)Urology Times staff
Advertisement
In this video, Eric A. Klein, MD, discusses the take-home messages from the recent JCO Precision Oncology study, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality,” for which he served as senior author. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.
Advertisement
Related to this article
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
3
FDA updates in urology: October 2026
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5